Delivering Unprecedented Access to Biosimilars in Global Markets
  • Developing, Manufacturing and Commercializing
    Biosimilar Products for Global Markets
Who We Are

EPIRUS is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. EPIRUS’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Learn More

News & Events

May 14, 2015

EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015

May 12, 2015

EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results 

Bookmark and Share